STR
John McKeon
Boston U. Questrom School of Business, United States
Felix Poege
Bocconi U., Italy
Jennifer Kao
UCLA Anderson School of Management, United States
Josh Feng
U. of Utah, David Eccles School of Business, United States
Lucy Xiaolu Wang
Assistant Professor at UMass Amherst, United States
Stefan Wagner
ESMT Berlin, Germany
David Hsu
The Wharton School, U. of Pennsylvania, United States
The pharmaceutical industry is one of the most significant sectors in the economy -- both in terms of economic impact and welfare implications due to health outcomes. Further, unique attributes of the industry and available data allow for robust empirical studies of strategy and innovation questions that are difficult to observe in many settings. This symposium showcases papers that study the implications of pharmaceutical M&A and IPOs on drug pricing and innovation as well as the link between competition and strategic patenting of pharmaceutical firms.
Author: Josh Feng – U. of Utah, David Eccles School of Business
Author: Thomas Hwang – Harvard Medical School
Author: Yunjuan Liu – U. of North Carolina, Chapel Hill
Author: Luca Maini – U. of North Carolina, Chapel Hill
Author: Jennifer Kao – UCLA Anderson School of Management
Author: Charu Gupta – UCLA Anderson School of Management
Author: Dennis Byrski – Max Planck Institute for Innovation and Competition
Author: Lucy Xiaolu Wang – Assistant Professor at UMass Amherst
Author: John McKeon – Boston U. Questrom School of Business
Author: Felix Poege – Bocconi U.
Author: Tim Simcoe – Boston U.